Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2014年 / 12卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [21] The spectrum of CD30+ T cell lymphoproliferative disorders in the skin
    Kartan, Saritha
    Johnson, William T.
    Sokol, Kelsey
    Alpdogan, Onder
    Gru, Alejandro A.
    Nikbakht, Neda
    Porcu, Pierluigi
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (01)
  • [22] Brentuximab Vedotin in primary cutaneous CD30+large-cell anaplastic T-Cell Lymphoma
    Moritz, R. K. C.
    Patsinakidis, N.
    Terras, S.
    Moellenhoff, K.
    Gambichler, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 921 - 921
  • [23] The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?
    Geller, S.
    Myskowski, P. L.
    Kim, Y. H.
    Moskowitz, A.
    Horwitz, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 571 - 571
  • [24] A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders
    Chen, Cynthia
    Gu, Yuhan D.
    Geskin, Larisa J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (01) : 121 - +
  • [25] Management of ALCL and other CD30+peripheral T-cell lymphomas with a focus on Brentuximab vedotin
    Nizamuddin, Imran
    Galvez, Carlos
    Pro, Barbara
    SEMINARS IN HEMATOLOGY, 2021, 58 (02) : 85 - 94
  • [26] Cutaneous Lymphomas - Part I: Mycosis Fungoides, Sezary Syndrome, and CD30+ Cutaneous Lymphoproliferative Disorders
    Pujol, R. M.
    Gallardo, F.
    ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (01): : 14 - 23
  • [27] Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas
    Ribereau-Gayon, Emmanuel
    Donzel, Marie
    Pham, Felix
    Romain-Scelle, Nicolas
    Perier-Muzet, Marie
    Balme, Brigitte
    Traverse-Glehen, Alexandra
    Ghesquieres, Herve
    Dalle, Stephane
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1424 - 1432
  • [28] Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas
    Stamatopoulou S.
    memo - Magazine of European Medical Oncology, 2013, 6 (4) : 275 - 277
  • [29] CD30+ leukemic cutaneous T-cell lymphoma
    Ellis, Ariana
    Christensen, Luisa F.
    Sharma, Timmie
    Meyerson, Howard
    Kord, Honda
    Cooper, Kevin D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 530 - 532
  • [30] A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas
    Maakaron, J.
    Huang, Y.
    Brammer, J.
    Chung, C.
    William, B.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S28 - S28
12345